Bionest

ASH 2021 Update: Part 2

A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.

Bionest

ASH 2021 Update: Part One

Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021

Bionest

What’s Next for mRNA?

Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?

Bionest

Bifunctional Antibodies: The Next Generation of Immuno-oncology Agents

Immuno-oncology agents, particularly checkpoint inhibitors, have moved to the forefront of cancer research and treatment in recent years. Indeed, the discovery that cancer could be treated by activating the immune system was honored with a Nobel Prize in 2018. But, as revolutionary as immuno-oncology drugs have been for the cancer field, many patients still do...

Bionest

Machine Learning and Drug R&D

We recently wrote about the growing use of machine learning and artificial intelligence (AI) in healthcare. That blog post talked primarily about the expanding applications of AI in clinical diagnostics, based on AI’s superior abilities in pattern recognition. Within the pharmaceutical industry, however, machine learning technologies hold the most potential for revolutionizing drug discovery and...